MAY 03, 2018 1:48 AM PDT

Treating Migraines with Less Side-Effects

WRITTEN BY: Nouran Amin

According to a 2013 Global Burden of Disease Study and the World Health Organization (WHO), migraine makes the list as the sixth highest cause worldwide for years lost due to disability.

Now, scientists have stumbled upon a side-effect free treatment option for chronic migraines. These side-effects that are usually accompanied with conventional treatments include fatigue, racing heartbeat, or nausea.

The discovered drug is erenumab which works against migraines to inhibit pain signals by targeting a receptor for calcitonin gene-related peptide (CGRP). According to the American Academy of Neurology, CGRP is responsible for the pain trsamiiosn. With erenumab, the drug works to inhint the nerves to which CGRP peptide binds, ebentiaull blocking the pain.

To test the effectiveness of the drug, investigators examined 246 people who are considered “more difficult to treat” noted by study author Uwe Reuter in a news release. The participants received injections of either 140 milligrams of erenumab or a placebo once every month for a total of three months.

“Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief,” explains Uwe Reuter said, “More research is now needed to understand who is most likely to benefit from this new treatment.” However, one disadvantage from this study was that researchers evaluated patients over a three-month period.

Current treatment options for migraines include OTC counter NSAIDs or dedicated triptans. These treatment options come with their own side effects such as drowsiness, dizziness or slow-thinking. “There’s no current dedicated migraine prevention medication,” says Dr. Michael R. Silver, an assistant professor in neurology at Emory University. “We borrow from other fields and use mostly anti-seizure medicines, blood pressure medicines or anti-depressants for migraine prevention.”

However, erenumabs provide promising treatment. “We’ve known CGRP have been involved in migraines for years and now, we’re finally coming out with medicines to address what is likely the root cause of migraine pain.”

Although erenumab is currently up for approval by the FDA, one downside might be the cost of having this treatment. Regardless, Dr. Silver believes that “this will hopefully usher in the new era of migraine treatment”.

Sources: American Academy of Neurology

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 15, 2020
Immunology
APR 15, 2020
Does COVID-19 Attack the Immune System like HIV?
Researchers from the US and China have found that COVID-19 can destroy T cells, a type of lymphocyte that plays a key ro ...
APR 15, 2020
Neuroscience
APR 15, 2020
How Magic Mushrooms Restructure the Brain
For some time now, researchers have suspected that psilocybin, the hallucinogen chemical present in ‘magic mushroo ...
APR 20, 2020
Cancer
APR 20, 2020
Expanding the Diagnostic Toolkit in Cancer Research with isomiRNAs
Esophageal cancers are one of the more common cancers around the world, with an unfortunately poor prognosis. The five-y ...
APR 20, 2020
Drug Discovery & Development
APR 20, 2020
First Successful Vaccine for Middle-East Respiratory Syndrome
Researchers have successfully completed the first-in-human clinical trial for a vaccine against MERS (Middle East Respir ...
MAY 09, 2020
Cancer
MAY 09, 2020
Examining a Combination Therapy Against Gastric Cancer
Often when it comes to treatments for cancer, designing or discovering new leads can take years. One of the common pract ...
MAY 21, 2020
Drug Discovery & Development
MAY 21, 2020
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repu ...
Loading Comments...